












2007 Life Sciences

Life sciences leaders turn to WilmerHale for legal advice and business advantage. We provide incisive solutions to the business challenges facing biotechnology, pharmaceutical, healthcare and medical device companies at all stages of growth. For over four decades, we have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, patent prosecution and portfolio development, licensing agreements and landmark collaborations, and have defended their innovations in critical patent litigation.



Counsel of Choice to Life Sciences Leaders...from Biotech to Medical Devices.

Venture Capital and PIPEs Financings

 \$53,000,000 Third Round March 2007	 \$36,000,000 First Round August 2007	 \$25,500,000 Fourth Round April 2007	 \$15,000,000 First Round April 2007	
 \$12,100,000 First Round May 2007	 \$20,000,000 Fourth Round February 2007	 \$17,000,000 Third Round October 2007	 \$32,000,000 Second Round August 2007	 \$35,000,000 Late Stage June 2007

Public Offerings and Rule 144A Placements

 Public Offering of Common Stock \$60,190,000 Counsel to Underwriters September 2007	 Initial Public Offering of Common Stock \$49,594,000 Counsel to Issuer August 2007	 Public Offering of Common Stock \$96,153,000 Counsel to Underwriters April 2007	
 Initial Public Offering of Common Stock \$86,250,000 Counsel to Underwriters May 2007	 Public Offering of Common Stock \$19,760,000 Counsel to Issuer May 2007	 Rule 144A Placement of 2.50% Convertible Senior Notes due 2014 \$125,000,000 Counsel to Issuer June 2007	 Public Offering of Common Stock \$138,000,000 Counsel to Underwriters May 2007

Strategic Alliances and Collaborations

 Collaboration with Roche for RNAi therapeutics	 Formation of public-private consortium to identify genomic markers linked to adverse drug reactions	 Oncology collaboration with Merck KGaA for toll-like receptor 9 agonists	 Drug development collaboration with Sandoz	 Reacquisition of European rights to anticoagulant product from Nycomed
 License from WARF for cell culture media and surfaces	 Pain collaboration with Pfizer for compounds that modulate sodium ion channels	 License of United States rights to topical non-steroidal anti-inflammatory drug from IDEA	 Licensing advice for drug development and commercialization agreements	

Mergers and Acquisitions

 acquisition by Hospira \$2,000,000,000 February 2007 (US antitrust counsel)	 acquisition by GSK £230,000,000 January 2007	 acquisition by Bristol-Myers Squibb \$430,000,000 October 2007	 acquisition by Roche \$140,000,000 May 2007	 acquisition by ViaCell \$300,000,000 November 2007
 acquisition by Amgen \$300,000,000 July 2007	 acquisition of APEX International Clinical Research Co. \$1,700,000,000 (New Taiwan Dollars) September 2007	 acquisition of Priority Air Holdings \$165,000,000 October 2007	 acquisition by Biogen Idec \$120,000,000 (including earnout) January 2007	

wilmerhale.com



Product grown from well-managed forests, controlled sources and recycled wood or fiber
www.fsc.org Cert. No. C-070964
© 1996 Forest Stewardship Council

WilmerHale recognizes its corporate responsibility to environmental stewardship.